KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) Operating Margin: 2009-2025

Historic Operating Margin for Neogenomics (NEO) over the last 17 years, with Sep 2025 value amounting to -14.38%.

  • Neogenomics' Operating Margin fell 175.00% to -14.38% in Q3 2025 from the same period last year, while for Sep 2025 it was -17.04%, marking a year-over-year decrease of 272.00%. This contributed to the annual value of -13.94% for FY2024, which is 427.00% up from last year.
  • As of Q3 2025, Neogenomics' Operating Margin stood at -14.38%, which was up 45.23% from -26.27% recorded in Q2 2025.
  • Over the past 5 years, Neogenomics' Operating Margin peaked at -10.70% during Q4 2024, and registered a low of -44.40% during Q1 2022.
  • In the last 3 years, Neogenomics' Operating Margin had a median value of -15.92% in 2023 and averaged -17.02%.
  • Its Operating Margin has fluctuated over the past 5 years, first slumped by 3,746bps in 2021, then skyrocketed by 1,884bps in 2023.
  • Over the past 5 years, Neogenomics' Operating Margin (Quarterly) stood at -33.06% in 2021, then soared by 1,404bps to -19.02% in 2022, then spiked by 708bps to -11.94% in 2023, then surged by 124bps to -10.70% in 2024, then crashed by 175bps to -14.38% in 2025.
  • Its last three reported values are -14.38% in Q3 2025, -26.27% for Q2 2025, and -16.56% during Q1 2025.